Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK)
HKD 1.66
(3.75%)
HKD 1.66
(3.75%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 44.95 Million CNY | -33.17% |
| 2022 | 67.26 Million CNY | -24.18% |
| 2021 | 88.71 Million CNY | 116.72% |
| 2020 | 40.93 Million CNY | 309.54% |
| 2019 | 9.99 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 38.28 Million CNY | -14.84% |
| 2024 Q2 | 38.28 Million CNY | 0.0% |
| 2023 Q2 | 58.33 Million CNY | 0.06% |
| 2023 FY | 44.95 Million CNY | -33.17% |
| 2023 Q1 | 58.3 Million CNY | -13.33% |
| 2023 Q3 | 44.04 Million CNY | -24.5% |
| 2023 Q4 | 44.95 Million CNY | 2.08% |
| 2022 Q2 | 84.1 Million HKD | 0.0% |
| 2022 FY | 67.26 Million CNY | -24.18% |
| 2022 Q4 | 67.26 Million CNY | 1.2% |
| 2022 Q3 | 66.46 Million CNY | -20.97% |
| 2021 Q4 | 88.71 Million HKD | 0.0% |
| 2021 FY | 88.71 Million CNY | 116.72% |
| 2020 FY | 40.93 Million CNY | 309.54% |
| 2019 FY | 9.99 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 152.81 Million HKD | 70.582% |
| CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 99.363% |